Researchers have discovered a panel of 13 blood proteins that may be effective biomarkers to detect malignant mesothelioma, according to a study published Oct. 3 in the open access journal PLOS ONE by Rachel Ostroff from the company SomaLogic, which developed the new test, and colleagues at other institutions.
Malignant mesothelioma is a rare, aggressive form of lung cancer that can develop after prolonged exposure to asbestos. Because early diagnosis is difficult, most patients face a poor prognosis and have few options for treatment. In the study, authors compared proteins in the blood of asbestos-exposed individuals without the disease to blood proteins in asbestos-exposed mesothelioma patients to identify 13 proteins that are linked to the disease, including in the early stages.
According to the researchers, the discovery of the new blood-based proteins linked to the disease could help to develop better, less invasive diagnostic tests to detect the disease at earlier stages.
Source: Eurekalert
